These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22098291)

  • 1. The quality of three decision-analytic diabetes models: a systematic health economic assessment.
    Becker C; Langer A; Leidl R
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):751-62. PubMed ID: 22098291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the CORE Diabetes Model against epidemiological and clinical studies.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S27-40. PubMed ID: 15324514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision support tools to optimize economic outcomes for type 2 diabetes.
    Shaya FT; Chirikov VV
    Am J Manag Care; 2011 Nov; 17 Suppl 14():S377-83. PubMed ID: 22214425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A disease management programme for patients with diabetes mellitus is associated with improved quality of care within existing budgets.
    Steuten LM; Vrijhoef HJ; Landewé-Cleuren S; Schaper N; Van Merode GG; Spreeuwenberg C
    Diabet Med; 2007 Oct; 24(10):1112-20. PubMed ID: 17672862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost analysis of community screening for diabetes in the central Wisconsin Medicare population (results from the MetaStar pilot project in Wausau).
    Lee DS; Remington P; Madagame J; Blustein J
    WMJ; 2000 Jun; 99(3):39-43. PubMed ID: 10927980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Lammert M; Oglesby A; Hayes C; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S59-66. PubMed ID: 15324517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Disease modelling in diabetes mellitus].
    Schramm W; Schöffski O; Görtz A; Liebl A
    Dtsch Med Wochenschr; 2004 Oct; 129(43):2305-10. PubMed ID: 15483770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of seven IVF strategies: results of a Markov decision-analytic model.
    Fiddelers AA; Dirksen CD; Dumoulin JC; van Montfoort AP; Land JA; Janssen JM; Evers JL; Severens JL
    Hum Reprod; 2009 Jul; 24(7):1648-55. PubMed ID: 19318703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
    Stylopoulos N; Gazelle GS; Rattner DW
    Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of type 2 diabetes screening: results from recently published studies.
    Icks A; Rathmann W; Haastert B; John J; Löwel H; Holle R; Giani G;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S167-71. PubMed ID: 16032536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges.
    Earnshaw SR; Wilson M; Mauskopf J; Joshi AV
    Value Health; 2009 Jun; 12(4):507-20. PubMed ID: 19900253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system.
    Bahia LR; Araujo DV; Schaan BD; Dib SA; Negrato CA; Leão MP; Ramos AJ; Forti AC; Gomes MB; Foss MC; Monteiro RA; Sartorelli D; Franco LJ
    Value Health; 2011; 14(5 Suppl 1):S137-40. PubMed ID: 21839888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease.
    Roze S; Liens D; Palmer A; Berger W; Tucker D; Renaudin C
    Curr Med Res Opin; 2006 Dec; 22(12):2549-56. PubMed ID: 17166337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.